Search
Lexicon Pharmaceuticals Inc
LXRXAdd to Watchlist
2.320USD
-0.020-0.85%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
843.24MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.85%
5 Days
+1.31%
1 Month
+22.75%
6 Months
+103.51%
Year to Date
+101.74%
1 Year
+153.30%
Key Figures
2.350Open
2.440High
2.63MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.72%Turnover Ratio
2.340Prev. Close
2.270Low
4.19MTurnover
LossP/E Static
7.84P/B
0.00%Div Yield TTM
-9.21%ROA
2.53052wk High
0.44Volume Ratio
-200.40MNet Profit
363.47MShares
-0.0714EPS TTM
1.06Beta
-16.01%ROE
0.61552wk Low
7.26%Amplitude
99.49%Gross Margin
843.24MMarket Cap
5.27Reward/Risk
5.03%Risk Rate
TradingKey Stock Score of Lexicon Pharmaceuticals Inc
Currency: USD Updated: 2026-07-02Key Insights
Lexicon Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 57 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.77.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Lexicon Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Lexicon Pharmaceuticals Inc Highlights
StrengthsRisks
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the research and development of pilavapadin, LX9851 and sotagliflozin and the commercialization of INPEFA. It is developing pilavapadin (LX9211), an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. It has completed three Phase II clinical trials evaluating the safety and tolerability of pilavapadin and its effects on diabetic peripheral neuropathic pain (DPNP) and neuropathic pain. It is developing LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic disorders and is conducting preclinical development of LX9851 in preparation for filing an investigational new drug application. It is commercializing INPEFA (sotagliflozin), an orally delivered small molecule drug, in the United States to reduce the risk of cardiovascular death, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 4036.46% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 49.80M.
Undervalued
The company’s latest PE is -32.49, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 301.10M shares, increasing 2.34% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 884.79 shares of this stock.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
3.770
Target Price
+42.80%
Upside Space
Lexicon Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Lexicon Pharmaceuticals Inc Info
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the research and development of pilavapadin, LX9851 and sotagliflozin and the commercialization of INPEFA. It is developing pilavapadin (LX9211), an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. It has completed three Phase II clinical trials evaluating the safety and tolerability of pilavapadin and its effects on diabetic peripheral neuropathic pain (DPNP) and neuropathic pain. It is developing LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic disorders and is conducting preclinical development of LX9851 in preparation for filing an investigational new drug application. It is commercializing INPEFA (sotagliflozin), an orally delivered small molecule drug, in the United States to reduce the risk of cardiovascular death, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus.
Ticker SymbolLXRX
CompanyLexicon Pharmaceuticals Inc
CEOExton (Michael)
Websitehttps://www.lexpharma.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52983.700
+141.200 (+0.27%)
29558.700
+247.300 (+0.84%)
7501.800
+30.300 (+0.41%)
15105.000
+302.000 (+2.04%)
69496.000
+1348.000 (+1.98%)
6376.400
+23.600 (+0.37%)
68.923
+0.579 (+0.85%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4177.430
+55.520 (+1.35%)
FAQs
What is the current price of Lexicon Pharmaceuticals Inc (LXRX)?
The current price of Lexicon Pharmaceuticals Inc (LXRX) is 2.32.
What is the symbol of Lexicon Pharmaceuticals Inc?
The ticker symbol of Lexicon Pharmaceuticals Inc is LXRX.
What is the 52-week high of Lexicon Pharmaceuticals Inc?
The 52-week high of Lexicon Pharmaceuticals Inc is 2.53.
What is the 52-week low of Lexicon Pharmaceuticals Inc?
The 52-week low of Lexicon Pharmaceuticals Inc is 0.61.
What is the market capitalization of Lexicon Pharmaceuticals Inc?
The market capitalization of Lexicon Pharmaceuticals Inc is 843.24M.
Is Lexicon Pharmaceuticals Inc (LXRX) currently rated as Buy, Hold, or Sell?
According to analysts, Lexicon Pharmaceuticals Inc (LXRX) has an overall rating of Buy, with a price target of 3.77.
What is the Earnings Per Share (EPS TTM) of Lexicon Pharmaceuticals Inc (LXRX)?
The Earnings Per Share (EPS TTM) of Lexicon Pharmaceuticals Inc (LXRX) is -0.14.